Today's Rundown Pfizer mulling over COVID-19 R&D pact with BioNTech: report Dana-Farber, MD Anderson ban all business travel over COVID-19 Shionogi boosts Tetra Alzheimer's deal, nabs buyout option FDA sets Dec. PDUFA date for Urovant rival to Astellas drug Fred Hutch mandates remote working to curb COVID-19 Quest, LabCorp to launch nationwide coronavirus testing ahead of FDA review EuroBiotech Report—AstraZeneca's HQ overspend, Immunocore B round, Waksal-Redx, Cellectis and Boehringer FiercePharmaAsia—India restricts drug exports; Roche's Actemra fights COVID-19; Takeda assets sale Chutes & Ladders—Unity names Biogen vet Ghosh to CEO post Featured Story | | | Friday, March 6, 2020 Big Pharma Pfizer is already at work on antivirals aimed at dampening down COVID-19 in the already infected, but it's now mulling over a pact with partner BioNTech to develop a vaccine. |
|
|---|
|
Top Stories Friday, March 6, 2020 Dana-Farber Cancer Institute and MD Anderson Cancer Center have canceled all business travel. The travel bans are part of a wave of actions taken by healthcare organizations to limit the harm caused by the novel coronavirus now making inroads into the U.S. Friday, March 6, 2020 In a high-stakes game for both companies, Shionogi is doubling down on its Tetra R&D deal with a buyout option wedded to key data coming out this month. Friday, March 6, 2020 The FDA has accepted Urovant Sciences’ filing for approval of overactive bladder prospect vibegron, teeing the biotech up to find out whether it has won approval in the final few days of 2020. Friday, March 6, 2020 The Fred Hutchinson Cancer Research Center is making its Seattle-based staff work from home in light of the emergence of a cluster of coronavirus cases in the city. The precautionary action comes as biopharma companies are starting to pull back from face-to-face events to cut the risk of their employees catching the virus. Thursday, March 5, 2020 Two of the nation’s largest clinical testing providers are launching their own assays for the novel coronavirus—moving forward this week after the FDA gave high-tech labs the green light to operate tests before receiving any agency review or authorization. Thursday, March 5, 2020 In this week's EuroBiotech Report, AstraZeneca's headquarter spending spirals, Immunocore raised $130 million and Sam Waksal ends attempt to buy Redx. Friday, March 6, 2020 India has halted export of 26 active ingredients and drugs as it faces supply hiccups from China due to the coronavirus. Roche's arthritis med Actemra is recommended by Chinese authorities to tackle COVID-19. Takeda sold its old U.S. HQ and is offloading 18 drugs in Latin America for $940 million total. And more. Friday, March 6, 2020 Unity taps Biogen R&D chief Ghosh to CEO role; Vir's Scangos named COVID-19 czar at BIO; Altavant names Boehringer alum as CMO. Enrollment Showcase | | | Presented by: Global EMBA for Healthcare & the Life Sciences, University of Toronto Prepare to step up in your career, build the expertise you need to reshape your organization, and explore opportunities worldwide. |
|
|---|
|
Resources Sponsored by: Metabolon Metabolomics can help you streamline your drug development process by providing the framework to make a stronger, more confident, and more valuable case for a molecule in a shorter timeframe. Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Reprints Desk/Research Solutions 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Baxter When different drug products are produced in shared facilities, potential for cross-contamination needs to be addressed. Outsourcing to a CMO with experience in multiproduct facilities can be an option. Sponsored by: WCG Metrics Champion Consortium Ineffective measurement could mean wasting both time and money. This whitepaper showcases a custom-built Metric Maturity Model that helps illustrate and define the process for measuring the right things the right way. Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates by implementing the right methodology with a focus on behavior change. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. BioBasics 101: The Biology of Biotech March 26-27, 2020 | Boston, MA Drug Discovery Chemistry – Choose from 45 Presentations from Top Pharma April 13-17, 2020 | San Diego, CA Medical Affairs Strategic Summit (MASS) East April 14-16, 2020 | New Brunswick, NJ BioBasics 101: The Biology of Biotech April 16-17, 2020 | Philadelphia, PA Drug Development Immersion April 23-24, 2020 | Boston, MA 2nd Annual World Pharma Week: Driving Innovation in Drug R&D June 2-4, 2020 | Boston, MA European Healthcare Compliance Certificate Program June 2-5, 2020 | Paris, France BIO International Convention June 8-11, 2020 | San Diego, CA U.S. Healthcare Compliance Certificate Program June 8-10, 2020 | Newark, NJ Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. | 